'Newman c' presentation slideshows

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention . TNT: Study Design Treating to New Targets. Patient Population. Clinically evident CHD LDL-C 130 ? 250 mg/dL following up to 8-week washout and 8-week open-label run-in with atorvastatin 10 mg.

459 views • 24 slides